Pharmaceutical Strategic Outlook: The Trouble with Alliances
Executive Summary
At Windhover's March 2008 Pharmaceutical Strategic Outlook meeting one overriding theme was an alliance paradox: values continue to rise and deals provide an increasingly important source of funds for biotechs, yet public investors don't seem to like these deals. Plus: a discussion of big-pharma outlicensing and the importance of CFOs in pharma strategy.
You may also be interested in...
Array Biopharma Wins Two Important Deals In Six Months, But Wall Street Shrugs
To management's frustration, the biotech's deals with Novartis and Amgen haven't helped its market cap, one more sign that validating deals with Big Pharma don't move investors.
Dealmaking When Pharma's the Only Game in Town
With no public market to provide competition, the theory among biotech's optimists was that Big Pharma would step in and buy lots of bargains. But cheap prices and easy availability haven't increased drug company appetites: They will only buy what they really want. Deal volumes, both for M&A and alliances, are falling, while Big Pharma has learned to put more of the risk back on biotech. What will change this dynamic, putting more bargaining into biotech hands, is the revival of the public market - and there are hints that such a revival may be on the way.
Best of the Blog: IN VIVO, June 2008
In May, Windhover's editorial staff posted 35 articles to the blog, covering biopharma, device and diagnostics R&D, business development, regulatory and commercial news. Here are a few of our favorite posts that didn't make it into stories covered elsewhere in this month's magazine: Changing of the Change Agents: Exit Wyeth's Ruffolo, Enter Orbimed's Dolsten; Cimzia Launch: Nothing Simple About It; Lundbeck Thanks Myriad For the Memories; Takeda's Millions Buy a Lot of Beer.